Sarepta Therapeutics (SRPT) Shorts Squeezed After Eteplirsen Receives FDA Approval

September 19, 2016 11:27 AM EDT Send to a Friend
Sarepta Therapeutics (NASDAQ: SRPT) shorts were pressured after the FDA approved its DMD ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login